The Biggest Biotech Wins of the Week

See who released the best clinical results during the week ending April 18.

Apr 21, 2014 at 6:30PM

The iShares Nasdaq Biotechnology Index finally put up some gains last week as some big names released great news. It looks like GlaxoSmithKline (NYSE:GSK) might have an oral psoriasis candidate. Hemophilia giant Baxter (NYSE:BAX) might be adding another therapy to its successful franchise. The biggest win of the week, however, goes to Intercept Pharmaceuticals (NASDAQ:ICPT). The clinical stage biotech fed another morsel to the hungry optimists holding up its industry leading gains.

Try, try again
To top off a whirlwind week of great news, GlaxoSmithKline finally hit a primary endpoint with JAK1 inhibitor GSK2586184. Preliminary data from a mid-stage study showed a significant number of chronic plaque psoriasis patients receiving the therapy achieved a 75% improvement from baseline.

Glaxo licensed the candidate from Belgian clinical stage biotech Galapagos just over two years ago. The partnership had grown a bit tense after the immuno-modulator hit a wall in previous studies. Glaxo stopped a phase 2 lupus trial at the first interim analysis due to lack of effect. It also put an exploratory phase 1-2 ulcerative colitis trial on hold.

As a small molecule drug, orally delivered JAK inhibitors have a strong advantage over currently successful antibodies. Unfortunately Glaxo is hardly a first mover in this class. Pfizer's (NYSE:PFE) JAK inhibitor Xeljanz is in the middle of two pivotal studies for plaque psoriasis. Pfizer expects to report top-line results from those studies later this quarter.

Another drug in the franchise
It looks like Baxter will soon add another bleeding disorder drug to its industry leading hemophilia franchise. In a late-stage trial, recombinant von Willebrand factor BAX 111 smashed through its primary endpoint. The replacement therapy successfully treated bleeding episodes in all 22 patients.

Von Willebrand disease is the most commonly inherited bleeding disorder. It's characterized by an insufficient level of the clotting factor that bears its name. About 1% of the population has the disease, but only about one in 10,000 people show symptoms serious enough to require treatment.

Baxter intends to file an application with the FDA for on-demand treatment with BAX 111 before the end of the year. A study of the recombinant factor as a prophylactic treatment should also begin some time this year.

Effective and fast
The biggest winner from last week is easily Intercept Pharmaceuticals. Last month the company announced preliminary results from a late stage study with its bile acid analog. Obeticholic acid (OCA) reached its primary endpoint of significantly reducing serum alkaline phosphatase -- a symptom of liver damage -- in patients with primary biliary cirrhosis. Last weekend the company released further details showing some patients displaying a positive impact from the drug after just two weeks of treatment, with peak effectiveness at 6 months.

Primary biliary cirrhosis (PBC) is a life threatening disease that primarily affects about 0.1% of women over 40. Currently ursodiol is the only approved treatment, but it's not terribly effective. Roughly half of PBC patients fail to respond adequately to ursodiol, leaving a large population with unmet need.

The opportunity wasn't lost on investors when the first hints of the OCA's efficacy sent the stock rocketing upwards. Like most clinical stage biotechs, it has given up a great deal in the past few weeks, despite the encouraging results.

ICPT Chart

ICPT data by YCharts

Following the above trial, Intercept may have collected enough data to support a new drug application for treatment of primary biliary cirrhosis patients that fail to respond to ursodiol. While the results make an approval seem increasingly likely, there are some important pitfalls to watch out for.

The first stems from cardiovascular events reported during a trial separate from the one above. The events weren't significantly related to the therapy, but any more could send shares plummeting. Also, Intercept believes the FDA will consider an application without long-term outcome data, but nothing is set in stone. If the agency changes its mind, it might take several years longer to bring OCA to the market.

3 stocks to own for the rest of your life
Tired of the biotech ups and downs? As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Baxter International. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers